Gastrointestinal stromal tumors, somatic mutations and candidate genetic risk variants
- PMID: 23637977
- PMCID: PMC3630216
- DOI: 10.1371/journal.pone.0062119
Gastrointestinal stromal tumors, somatic mutations and candidate genetic risk variants
Abstract
Gastrointestinal stromal tumors (GISTs) are rare but treatable soft tissue sarcomas. Nearly all GISTs have somatic mutations in either the KIT or PDGFRA gene, but there are no known inherited genetic risk factors. We assessed the relationship between KIT/PDGFRA mutations and select deletions or single nucleotide polymorphisms (SNPs) in 279 participants from a clinical trial of adjuvant imatinib mesylate. Given previous evidence that certain susceptibility loci and carcinogens are associated with characteristic mutations, or "signatures" in other cancers, we hypothesized that the characteristic somatic mutations in the KIT and PDGFRA genes in GIST tumors may similarly be mutational signatures that are causally linked to specific mutagens or susceptibility loci. As previous epidemiologic studies suggest environmental risk factors such as dioxin and radiation exposure may be linked to sarcomas, we chose 208 variants in 39 candidate genes related to DNA repair and dioxin metabolism or response. We calculated adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for the association between each variant and 7 categories of tumor mutation using logistic regression. We also evaluated gene-level effects using the sequence kernel association test (SKAT). Although none of the association p-values were statistically significant after adjustment for multiple comparisons, SNPs in CYP1B1 were strongly associated with KIT exon 11 codon 557-8 deletions (OR = 1.9, 95% CI: 1.3-2.9 for rs2855658 and OR = 1.8, 95% CI: 1.2-2.7 for rs1056836) and wild type GISTs (OR = 2.7, 95% CI: 1.5-4.8 for rs1800440 and OR = 0.5, 95% CI: 0.3-0.9 for rs1056836). CYP1B1 was also associated with these mutations categories in the SKAT analysis (p = 0.002 and p = 0.003, respectively). Other potential risk variants included GSTM1, RAD23B and ERCC2. This preliminary analysis of inherited genetic risk factors for GIST offers some clues about the disease's genetic origins and provides a starting point for future candidate gene or gene-environment research.
Conflict of interest statement
Figures
Similar articles
-
KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs).Semin Diagn Pathol. 2006 May;23(2):91-102. doi: 10.1053/j.semdp.2006.08.006. Semin Diagn Pathol. 2006. PMID: 17193822 Review.
-
Tyrosine-kinase mutations in c-KIT and PDGFR-alpha genes of imatinib naïve adult patients with gastrointestinal stromal tumours (GISTs) of the stomach and small intestine: relation to tumour-biological risk-profile and long-term outcome.Clin Transl Oncol. 2012 Aug;14(8):619-29. doi: 10.1007/s12094-012-0851-x. Epub 2012 Jul 18. Clin Transl Oncol. 2012. PMID: 22855146
-
[The importance of mutational status in prognosis and therapy of GIST].Recenti Prog Med. 2015 Jan;106(1):17-22. doi: 10.1701/1740.18950. Recenti Prog Med. 2015. PMID: 25621775 Italian.
-
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.J Clin Oncol. 2003 Dec 1;21(23):4342-9. doi: 10.1200/JCO.2003.04.190. J Clin Oncol. 2003. PMID: 14645423 Clinical Trial.
-
Correlation of imatinib resistance with the mutational status of KIT and PDGFRA genes in gastrointestinal stromal tumors: a meta-analysis.J Gastrointestin Liver Dis. 2013 Dec;22(4):413-8. J Gastrointestin Liver Dis. 2013. PMID: 24369323 Review.
Cited by
-
The rs17084733 variant in the KIT 3' UTR disrupts a miR-221/222 binding site in gastrointestinal stromal tumour: a sponge-like mechanism conferring disease susceptibility.Epigenetics. 2019 Jun;14(6):545-557. doi: 10.1080/15592294.2019.1595997. Epub 2019 Apr 13. Epigenetics. 2019. PMID: 30983504 Free PMC article.
-
Molecular predictive markers in tumors of the gastrointestinal tract.World J Gastrointest Oncol. 2016 Nov 15;8(11):772-785. doi: 10.4251/wjgo.v8.i11.772. World J Gastrointest Oncol. 2016. PMID: 27895815 Free PMC article. Review.
-
APOE polymorphisms and cognitive functions in patients with brain tumors.Neurology. 2014 Jul 22;83(4):320-7. doi: 10.1212/WNL.0000000000000617. Epub 2014 Jun 18. Neurology. 2014. PMID: 24944262 Free PMC article.
-
Personalized Medicine in Gastrointestinal Stromal Tumor (GIST): Clinical Implications of the Somatic and Germline DNA Analysis.Int J Mol Sci. 2015 Jul 9;16(7):15592-608. doi: 10.3390/ijms160715592. Int J Mol Sci. 2015. PMID: 26184165 Free PMC article. Review.
-
Polymorphisms in DNA repair genes in gastrointestinal stromal tumours: susceptibility and correlation with tumour characteristics and clinical outcome.Tumour Biol. 2016 Oct;37(10):13413-13423. doi: 10.1007/s13277-016-5276-7. Epub 2016 Jul 27. Tumour Biol. 2016. PMID: 27460091
References
-
- Miettinen M, Lasota J (2001) Gastrointestinal stromal tumors--definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch. . 438: 1–12. - PubMed
-
- Gastrointestinal Stromal Tumors Treatment (PDQ®) - National Cancer Institute. Available: http://www.cancer.gov/cancertopics/pdq/treatment/gist/HealthProfessional.Accessed 2012 Oct 24 .
-
- Tran T, Davila JA, El-Serag HB (2005) The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1,458 cases from 1992 to 2000. Am J Gastroenterol. . 100: 162–168. - PubMed
-
- Corless CL, Heinrich MC (2008) Molecular pathobiology of gastrointestinal stromal sarcomas. Annu Rev Pathol. . 3: 557–586. - PubMed
-
- Perez EA, Livingstone AS, Franceschi D, Rocha-Lima C, Lee DJ, et al. (2006) Current incidence and outcomes of gastrointestinal mesenchymal tumors including gastrointestinal stromal tumors. J Am Coll Surg. . 202: 623–629. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous